

Flavia Zanaboni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/938754/publications.pdf>

Version: 2024-02-01

44
papers

2,100
citations

249298

26
h-index

312153

41
g-index

45
all docs

45
docs citations

45
times ranked

1841
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation of laparoscopic approach for type B radical hysterectomy: A comparison with open surgical operations. <i>European Journal of Surgical Oncology</i> , 2015, 41, 34-39.	0.5	78
2	Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 22.	1.0	29
3	Phase II Trial on Cisplatin-Adriamycin-Paclitaxel Combination as Neoadjuvant Chemotherapy for Locally Advanced Cervical Adenocarcinoma. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 729-734.	1.2	26
4	Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study. <i>European Journal of Cancer</i> , 2013, 49, 1065-1072.	1.3	26
5	Class III NSRH: Oncological outcome in 170 cervical cancer patients. <i>Gynecologic Oncology</i> , 2010, 119, 192-197.	0.6	18
6	Clinical and pharmacological phase I evaluation of Exherinâ„¢ (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. <i>Annals of Oncology</i> , 2009, 20, 741-745.	0.6	63
7	Quality of Life and Sexual, Bladder, and Intestinal Dysfunctions After Class III Nerve-Sparing and Class II Radical Hysterectomies. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 953-957.	1.2	52
8	Randomised trial of drains versus no drains following radical hysterectomy and pelvic lymph node dissection: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) study in 234 patients. <i>European Journal of Cancer</i> , 2007, 43, 1265-1268.	1.3	46
9	Nerve-sparing radical hysterectomy in cervical cancer: Evolution of concepts. <i>Gynecologic Oncology</i> , 2007, 107, S119-S121.	0.6	31
10	Surgical Treatment in FIGO Stage I Cervical Cancer: Evolution of Concepts. <i>Current Women's Health Reviews</i> , 2007, 3, 129-137.	0.1	0
11	Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. <i>European Journal of Surgical Oncology</i> , 2006, 32, 671-675.	0.5	105
12	Type II versus Type III Nerve-sparing Radical hysterectomy: Comparison of lower urinary tract dysfunctions. <i>Gynecologic Oncology</i> , 2006, 102, 256-262.	0.6	81
13	Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva. <i>Gynecologic Oncology</i> , 2006, 102, 333-337.	0.6	94
14	Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails. <i>Journal of Clinical Oncology</i> , 2005, 23, 1867-1874.	0.8	163
15	Nerve-sparing radical hysterectomy: a surgical technique for preserving the autonomic hypogastric nerve. <i>Gynecologic Oncology</i> , 2004, 93, 307-314.	0.6	119
16	â€˜State of the artâ€™ of radical hysterectomy; current practice in European oncology centres. <i>European Journal of Cancer</i> , 2004, 40, 375-378.	1.3	34
17	Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and Taxane. <i>Oncology</i> , 2004, 67, 376-381.	0.9	28
18	Microinvasive squamous cell cervical carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, 251-261.	2.0	19

#	ARTICLE	IF	CITATIONS
19	Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923). <i>European Journal of Cancer</i> , 2003, 39, 481-487.	1.3	37
20	Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group <i>Ann Oncol</i> 2003; 14: 441-448. <i>Annals of Oncology</i> , 2003, 14, 811.	0.6	0
21	Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. <i>Annals of Oncology</i> , 2003, 14, 441-448.	0.6	184
22	Microlaparoscopy: a new approach to the reassessment of ovarian cancer patients. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2000, 79, 427-430.	1.3	3
23	Microlaparoscopy: a new approach to the reassessment of ovarian cancer patients. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2000, 79, 427-430.	1.3	2
24	Clinical Value of Intraoperative Gross Examination in Endometrial Cancer. <i>Gynecologic Oncology</i> , 2000, 76, 357-361.	0.6	66
25	A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. <i>Annals of Oncology</i> , 2000, 11, 1035-1040.	0.6	23
26	Endometrial thickness in tamoxifen-treated patients: an independent predictor of endometrial disease. <i>Obstetrics and Gynecology</i> , 1999, 93, 1004-1008.	1.2	27
27	The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. , 1998, 82, 159-167.		34
28	A phase II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. <i>European Journal of Cancer</i> , 1997, 33, 592-595.	1.3	14
29	Nonclosure of Peritoneum at Radical Abdominal Hysterectomy and Pelvic Node Dissection: A Randomized Study. <i>Obstetrics and Gynecology</i> , 1997, 90, 622-627.	1.2	54
30	Octreotide in the Management of Bowel Obstruction in Terminal Ovarian Cancer. <i>Gynecologic Oncology</i> , 1996, 61, 345-348.	0.6	91
31	Determinants of Response to a Cisplatin-Based Regimen as Neoadjuvant Chemotherapy in Stage IB-IIIB Invasive Cervical Cancer. <i>Gynecologic Oncology</i> , 1996, 63, 62-65.	0.6	23
32	Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy. , 1996, 77, 128.		2
33	Diagnosis of pelvic masses with transabdominal color Doppler, CA 125 and ultrasonography. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1995, 74, 734-739.	1.3	35
34	Oral Ondansetron and Intravenous Dexamethasone in the Prevention of Cisplatin-Induced Emesis. <i>Oncology</i> , 1995, 52, 509-512.	0.9	5
35	Management of adnexal masses by operative laparoscopy. <i>Journal of Minimally Invasive Gynecology</i> , 1995, 2, 273-277.	1.4	17
36	Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen. <i>European Journal of Cancer</i> , 1994, 30, 1764-1768.	1.3	21

#	ARTICLE	IF	CITATIONS
37	Salvage chemotherapy for ovarian cancer recurrence: Weekly cisplatin in combination with epirubicin or etoposide. <i>Gynecologic Oncology</i> , 1991, 43, 24-28.	0.6	28
38	Prognostic factors in advanced epithelial ovarian cancer. <i>British Journal of Cancer</i> , 1990, 62, 444-450.	2.9	73
39	The impact of whole-abdomen radiotherapy on survival in advanced ovarian cancer patients with minimal residual disease after chemotherapy. <i>Gynecologic Oncology</i> , 1990, 39, 150-154.	0.6	26
40	Randomized Trial in Advanced Ovarian Cancer Comparing Cisplatin and Carboplatin. <i>Journal of the National Cancer Institute</i> , 1989, 81, 1464-1471.	3.0	135
41	EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). <i>Gynecologic Oncology</i> , 1988, 31, 439-444.	0.6	90
42	Tumor antigen CA 125 as a marker of ovarian epithelial carcinoma. <i>Gynecologic Oncology</i> , 1987, 28, 61-67.	0.6	54
43	Induction of cytotoxicity by interleukin-2 in t1 ³ -lymphoproliferative disorders. <i>International Journal of Cancer</i> , 1986, 37, 27-33.	2.3	15
44	Evaluation of the interaction of mononuclear phagocytes with ovarian carcinoma cells in a colony assay. <i>British Journal of Cancer</i> , 1986, 53, 47-52.	2.9	15